scorecardresearch
Add as a preferred source on Google
Friday, May 1, 2026
TopicCovid drug

Topic: Covid drug

Free Covid precaution doses for 18-59 age group from July 15 at govt centres

As part of Centre’s Azadi Ka Amrit Mahotsav, this initiative will continue for 75 days.

WHO recommends two new Covid drugs, in discussions to secure ‘equitable access’

Extent to which Baricitinib & Sotrovimab will save lives depends on how available, affordable they will be, says WHO. New guidelines advise against use of Remdesivir, Ivermectin.

WHO approves Glaxo and Eli Lilly drugs to treat Covid amid Omicron surge

Eli Lilly’s rheumatoid arthritis drug and GlaxoSmithKline's monoclonal antibody won the WHO nod.

Antiviral Molnupiravir not in govt Covid protocol, but ‘millions of doses’ distributed in a week

Pharma companies say doctors working in community settings have begun pre-ordering the drug, several manufacturers gearing up to meet demand.

Scientists launch hunt to find naturally Covid-resistant people, 1,000 volunteers to be enrolled

The study looks for people genetically resistant to SARS-CoV-2 virus — if such natural immunity exists. Candidates are one of a couple, where only one partner fell sick, despite close contact.

No benefits of Doxycycline found in UK Covid patients, write Oxford researchers in Lancet study

According to researchers, the drug that has been commonly used to treat Covid respiratory symptoms does not reduce recovery time, hospital admissions, or deaths related to Covid.

Has Covid exposed limitations of ‘secretive’ ICMR? Some experts think so

The ICMR has increasingly drawn criticism from India's doctors and scientists, who have questioned its drug recommendations & lack of transparency on data related to variants.

Pharma firms and diagnostics developers need to unite. They are catalysts for saving lives

Studies of drugs like remdesivir and hydroxychloroquine were underpowered and small, and the results were conflicting and, in many cases, inconclusive.

Molnupiravir helps in faster recovery of mild Covid patients, says Hetero after phase 3 trials

Hyderabad-based pharma company, Hetero, announced promising interim results of phase 3 trials and has approached DCGI for emergency use authorisation for the drug in India.

Why Covid drug Ivermectin remains popular despite warnings & lack of evidence on efficacy

University of Oxford has launched a large study to investigate the use of Ivermectin for Covid-19 treatment, amid guidelines across the world, warning against the use of the drug. 

On Camera

India’s real estate will meet the reality of agentic AI

New Delhi: The outsourcing industry, India’s largest white-collar employer, is a juggernaut that has all but stopped moving. The dollar revenue at the top...

Adani’s giant copper plant hits technical setbacks in first year

The 500,000 tonne-per-year plant produced just 94,000 tonnes of refined copper from April 2025 to February this year.

Indian drone tech company ideaForge signs MoU with Japanese firm to develop next-gen AI powered drones

By pairing Indian drone engineering with Japanese semiconductor expertise, the two firms aim to develop more advanced autonomous systems tailored to both defence & commercial use.

Trump, Netanyahu’s Iran gamble: The regime change rebound

American objectives are unmet. They neither have muscle nor motivation to resume the war. As for Iran, the regime didn’t just survive, it’s now led by more radical individuals.